Hospital Clinico Universitario de Valencia -ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2019

  1. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

    Haematologica, Vol. 104, Núm. 3, pp. 576-586

2018

  1. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia

    Leukemia, Vol. 32, Núm. 3, pp. 645-653

  2. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia

    Leukemia and Lymphoma, Vol. 59, Núm. 10, pp. 2318-2326

2015

  1. Non-coding recurrent mutations in chronic lymphocytic leukaemia

    Nature, Vol. 526, Núm. 7574, pp. 519-524

2014

  1. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome

    Blood, Vol. 123, Núm. 24, pp. 3790-3796

2013

  1. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome

    Leukemia, Vol. 27, Núm. 5, pp. 1100-1106